meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
3
mHCC - 1st line (L1)
10
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
versus all
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab alone
title
placebo
title
KEYNOTE-240, 2020 NCT02702401 mHCC - 2nd line (L2) 278/135
KEYNOTE-394, 2022 NCT03062358 mHCC - 2nd line (L2) 300/153
Pathology:
mHCC - 2nd line (L2);
mHCC - 2nd line (L2)
KEYNOTE-240, 2020
KEYNOTE-394, 2022
pembrolizumab alone
2
T1
T1
placebo
0
T0
T0